Write a paragraph for an article about treatment in two groups with and without

Treatment approaches for systemic lupus erythematosus (SLE) patients with alopecia differ primarily in addressing the specific autoimmune-mediated hair loss along with general lupus management.

Alopecia in SLE often manifests as part of disease-specific skin lesions, reflecting the inflammatory or autoimmune activity that damages hair follicles. Management thus includes both systemic lupus treatment and targeted alopecia therapy to prevent further hair loss and promote regrowth. For alopecia areata, which can co-occur with autoimmune conditions like SLE, initial management may involve topical or systemic immunosuppressants; recent approvals include baricitinib for severe alopecia areata, which has shown significant efficacy in improving hair regrowth by targeting Janus kinase pathways involved in autoimmunity NICE CKS,SmPC Baricitinib,SmPC Olumiant. Additionally, potent topical corticosteroids are an option for alopecia areata and may be employed adjunctively NICE CKS.

For patients with SLE without alopecia, treatment focuses on systemic control of inflammation and organ involvement using antimalarials like hydroxychloroquine, corticosteroids, immunosuppressants, and increasingly, biologics for refractory disease. These therapies help manage fatigue, skin and joint involvement, and other systemic manifestations NHS Lupus,SmPC Hydroxychloroquin,Xie et al. 2025.

The presence of alopecia, especially when diagnosed as alopecia areata or lupus-related scarring alopecia, may prompt more aggressive localized treatment including topical corticosteroids and possible use of recently licensed systemic agents such as baricitinib for alopecia areata or telitacicept in refractory lupus skin manifestations including rare lupus erythematosus panniculitis NICE CKS,SmPC Baricitinib,SmPC Litfulo,SmPC Olumiant,Xie et al. 2025. Biological therapies targeting B-cell survival factors (eg, telitacicept) show promise in severe lupus skin damage that may accompany alopecia, assisting in both systemic disease remission and skin lesion healing Xie et al. 2025.

In summary, SLE patients with alopecia require a combined approach addressing both systemic autoimmune activity and localized hair follicle inflammation, often blending traditional lupus treatments with specialized alopecia therapies. Those without alopecia typically receive standard SLE management without targeted hair loss treatments. Future treatment strategies increasingly incorporate biologic agents tailored to the patient’s disease phenotype, including alopecia presence or absence NICE CKS,NHS Lupus,SmPC Olumiant,Xie et al. 2025.